KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large-volume subcutaneous infusion solutions, this week presented data demonstrating nursing preference for the use of the KORU FreedomEdge Infusion System to administer subcutaneous oncology infusions in the clinic setting. The results of the case study were presented at the PODD 2024 Conference on October 28, 2024, in Boston, Massachusetts.
The objective of the Nursing Preference Study was to assess time spent with patients, impact on nursing and patient comfort, and overall nurse preference when comparing manual syringe administration versus mechanical pump administration with the KORU FreedomEdge Infusion System during subcutaneous oncology biologic drug infusions. The study was conducted by KORU Medical across 6 hospitals in Denmark with 33 nurses administering more than 3,000 infusions of a >10mL oncology drug with an average administration time of approximately 10 minutes.
- Increased Patient Interaction: 97% of nurses reported having more time to interact with patients while using the KORU FreedomEdge Infusion System versus manual syringe administration
- Reduced Nurse Discomfort: 81% of nurses experienced less hand pain while using the KORU FreedomEdge Infusion System compared to manual syringe administration
- Ease of Use: 91% of nurses found the KORU FreedomEdge Infusion System easier to use, with a shorter setup time compared to manual syringe administration
- Reduced Patient Discomfort: 73% of nurses observed less patient pain during infusions with the KORU FreedomEdge Infusion System versus manual syringe administration
- Recommended by Nurses: 97% of nurses would recommend the KORU FreedomEdge Infusion System over manual syringeadministration, citing ease of use and reduced discomfort as key reasons
Subcutaneous formulation of formerly intravenous biologics is a growing trend with oncology pharmaceutical manufacturers. There are five greater-than-5mL biologic oncology drugs that have been cleared for in-clinic administration by healthcare professionals for an estimated one million global infusions.1,2 Evidence indicates that subcutaneous administration of oncology therapy simplifies treatment protocol, reduces pressure on hospitals, and improves patients' quality of life.3 As further development of subcutaneous drug therapies increases, the optimization of drug administration has created a significant opportunity for drug delivery solutions like the KORU FreedomEdge Infusion System.
